Alkermes plc: Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness
- LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Alkermes